Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same system

Trial Details

NCT ID
NCT04838899
Phase
NA
Sponsor
Sunnybrook Health Sciences Centre
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Stereotactic Body Radiation Therapy (SABR)
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • ECOG performance status 0-1.
  • Histologic confirmation of prostate adenocarcinoma.
  • Documentation of metastatic, castration-resistant prostate cancer.
  • Patient being treated with abiraterone.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →